Literature DB >> 30032897

Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab.

I Hegemann1, C Ganter2, C C Widmer2, M Becker2, D Müller2, D R Spahn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30032897     DOI： 10.1016/j.bja.2018.04.025

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


× No keyword cloud information.
  3 in total

1.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

2.  Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Authors:  Mathias Ströhle; Christopher Rugg; Stefan Schmid; Dietmar Fries; Elgar Oswald
Journal:  Trauma Case Rep       Date:  2021-02-10

3.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.